Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Stopped The study was closed to accrual due to the end of the clinical development program with cixutumumab.

Conditions

• Large Cell Lung Carcinoma
• Lung Adenocarcinoma
• Recurrent Non-Small Cell Lung Carcinoma
• Stage IV Non-Small Cell Lung Cancer
• Bronchioloalveolar Lung Carcinoma

Interventions

• BIOLOGICAL: Bevacizumab
• DRUG: Carboplatin
• BIOLOGICAL: Cixutumumab
• DRUG: Paclitaxel

Sponsor

National Cancer Institute (NCI)